CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-15 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −20,300 | $7.25 | $147K | 942,886 |
| 2023-11-15 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −4,700 | $7.62 | $36K | 938,186 |
| 2023-11-15 | Secora Michael Chief Financial Officer | Shares withheld for taxes 10b5-1 | −7,172 | $7.18 | $51K | 931,014 |
| 2023-11-15 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,185,135 | ||
| 2023-11-14 | Borgeson Blake Director | Sale | −8,885 | $6.32 | $56K | 7,407,420 |
| 2023-11-14 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 950,686 |
| 2023-11-14 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $6.32 | $158K | 925,686 |
| 2023-11-14 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,222,635 | ||
| 2023-11-10 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 846,820 | ||
| 2023-11-10 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 836,820 | ||
| 2023-11-10 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,501,496 | ||
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 873,997 |
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Sale | −37,177 | $5.20 | $193K | 836,820 |
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Conversion | +4,000 | 4,000 | ||
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Sale | −4,000 | $5.14 | $21K | 0 |
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Conversion | +20,000 | 20,000 | ||
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Sale | −20,000 | $5.11 | $102K | 0 |
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Conversion | +1,000 | 1,000 | ||
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Sale | −1,000 | $5.14 | $5K | 0 |
| 2023-11-01 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 437,500 |
Page 29 of 41 · 805 trades